PDF) Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology
PDF) Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials